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Background: Bovine respiratory syncytial virus (BRSV) is a major cause of respiratory disease in cattle worldwide.
Calves are particularly affected, even with low to moderate levels of BRSV-specific maternally derived antibodies
(MDA). Available BRSV vaccines have suboptimal efficacy in calves with MDA, and published infection models in this
target group are lacking in clinical expression. Here, we refine and characterize such a model.
Results: In a first experiment, 2 groups of 3 calves with low levels of MDA were experimentally inoculated by
inhalation of aerosolized BRSV, either: the Snook strain, passaged in gnotobiotic calves (BRSV-Snk), or isolate no.
9402022 Denmark, passaged in cell culture (BRSV-Dk). All calves developed clinical signs of respiratory disease and
shed high titers of virus, but BRSV-Snk induced more severe disease, which was then reproduced in a second experiment
in 5 calves with moderate levels of MDA. These 5 calves shed high titers of virus and developed severe clinical
signs of disease and extensive macroscopic lung lesions (mean+/−SD, 48.3+/−12.0% of lung), with a pulmonary
influx of inflammatory cells, characterized by interferon gamma secretion and a marked effect on lung function.
Conclusions: We present a BRSV-infection model, with consistently high clinical expression in young calves with
low to moderate levels of BRSV-specific MDA, that may prove useful in studies into disease pathogenesis, or evaluations
of vaccines and antivirals. Additionally, refined tools to assess the outcome of BRSV infection are described, including
passive measurement of lung function and a refined system to score clinical signs of disease. Using this cognate host
calf model might also provide answers to elusive questions about human RSV (HRSV), a major cause of morbidity in
children worldwide.
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Bovine respiratory syncytial virus (BRSV), a pneumo-
virus in the family Paramyxoviridae, is highly prevalent
in cattle, with a significant economic impact as the most
important viral cause of bovine respiratory disease
(BRD) worldwide [1]. Despite the high seropositivity,
BRSV outbreaks occur frequently, peaking during the
winter months in temperate climates [2]. BRSV is
thought to be transmitted by direct and indirect routes,* Correspondence: jean-francois.valarcher@slu.se
1Department of Clinical Sciences, Swedish University of Agricultural Sciences,
Host Pathogen Interaction Group, Uppsala, Sweden
6Department of Virology, National Veterinary Institute, Immunology, and
Parasitology, Uppsala, Sweden
Full list of author information is available at the end of the article
© 2015 Blodörn et al.; licensee BioMed Centra
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.and possibly by aerosol over short distances [3], but all
the mechanisms of introduction and maintenance within
herds are not clear.
Severe disease is usually observed in calves less than
1 year old, and in particular between 1–3 months in
BRSV-endemic regions [4]. BRSV replication in the
upper and lower airways causes cellular damage and
dysfunction, and may lead to misdirected immune re-
sponses, which compound clinical signs of disease [5,6].
Most colostrum fed calves in endemic areas have
BRSV-specific maternally derived antibodies (MDA) in
serum, affording them limited protection from BRSV
infection during the first weeks of life, but having a
negative effect on the degree and duration of protectionl. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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in these animals has not always been fully satisfactory, and
the development of a safe and effective BRSV vaccine, with
a long duration of protection, therefore remains a high
priority for the cattle industry [1]. Furthermore, following
vaccination, exacerbated reaction to natural or experimen-
tal infection, although uncommon, has been described in
calves [8,9], and resembles that previously observed in
children immunized with an inactivated vaccine against the
genetically and antigenically closely related pneumovirus,
human RSV (HRSV) [10].
For these reasons, as well as to improve understanding
of the pathogenic mechanisms during an acute infection,
a clinically expressive BRSV model is needed to study
BRSV pathogenesis, and to evaluate the protective effi-
cacy of vaccine candidates and antivirals.
Several studies have attempted to reproduce field-like
BRSV disease in young calves with varying levels of
MDA, by administrating BRSV intranasally [11], intra-
tracheally [12-14], or by a combination of intranasal and
intratracheal route [14,15]. Some studies report severe
clinical disease following experimental BRSV infection,
but omit observed or methodological details that would
allow interstudy comparison (e.g. rectal temperature [16]).
Whereas most studies have failed to reproduce severe
clinical signs of disease, despite using high titers of virus
and repeated inoculations [17], studies utilizing inocula-
tion by inhalation of aerosol have been those most suc-
cessful [7,14,18-21], although this is not consistent [22].
Here, our objective was to improve and characterize a
BRSV model in calves, by selecting one of two inocula,
based on two different strains passaged in calves or in cell
culture, and used by two different research groups, to ob-
tain a model that would induce clinical signs comparable
to those observed in the field. In addition, we describe a
refined scoring system for clinical signs of disease, and
objective tools that can be used to monitor and assess
the effects of BRSV infection in calves.
Methods
Cells and viruses
The BRSV Snook strain was isolated in calf kidney cells
[11], and then passaged three consecutive times in
gnotobiotic calves by inoculation by respiratory route,
and prepared from bronchoalveolar lavage (BAL), as pre-
viously described [13] (BRSV-Snk inoculum). BRSV iso-
late no. 9402022 Denmark [5] was isolated in fetal lung
cells, passaged in bovine turbinate cells, and prepared as
described previously [21] (passage 8, BRSV-Dk inocu-
lum). Aliquots of the BRSV-Snk and BRSV-Dk inocula
were titrated by plaque assay using calf kidney cells, as
previously described [11]. Through inoculation of appro-
priate cell cultures and mycoplasmal or bacterial media,
all cells and virus preparations were determined to befree from bovine viral diarrhea virus and bacteria, in-
cluding mycoplasma (data not shown).
Animals
The calves included were male, of Swedish Holstein or
Swedish red and white breed, and originated from two
conventional dairy herds, both free from bovine viral
diarrhea virus. The herds were monitored for natural
BRSV infections through monthly analysis of BRSV-
specific IgG1 (see section Detection of BRSV-specific
antibodies) in bulk tank milk and in sera from calves,
heifers and cows. Herd 1 was monitored from 17 days
after the birth of the oldest calf, 1 day after the birth of
the second oldest, and before the birth of the remaining
calves in study 1. Herd 2, was monitored from 2 months
before birth of the oldest calf to be challenged with
BRSV in study 2.
For study 1, six calves (A1-3 and B1-3) were obtained
from herd 1. These calves had low levels of BRSV-specific
serum MDA on the day of challenge; mean 4.1 ± 4.8%
COD of kit positive at a dilution of 1:25, where ≤10%COD
positive is considered negative by the ELISA kit. In study
2, five calves (C1-5) were obtained from herd 2, all with
moderate levels of BRSV-specific serum MDA; mean
49 ± 30% COD positive, or log10 titer 2.0 ± 0.2, defined
as moderate. In addition, three calves (D1-3) were obtained
from herd 1 to act as uninfected controls.
Challenge and experimental design
Groups of calves were housed in an animal facility, in
separate rooms, with free access to clean water and
roughage, and additional daily rations of concentrate.
Each room had separate negative-pressure ventilation,
physical bio-barriers and protective clothing for all staff.
All calves were healthy on arrival, and no respiratory
clinical signs were observed during one week of acclima-
tion and quarantine. To minimize interference by bacterial
co-infections, all calves were treated with antibiotics for
five consecutive days (20 mg/kg/day procaine benzyl peni-
cillin intramuscularly). On post-infection day (PID) 0, all
calves were challenged by aerosol inhalation.
In study 1, calves were inoculated with either BRSV-
Snk (calves A1-3; 9 ± 3 weeks old) or BRSV-Dk (calves
B1-3; 9 ± 2 weeks old). Each dose of inoculum contained
104.0 (BRSV-Snk) or 104.4 (BRSV-Dk) pfu of BRSV, diluted
in Dulbecco’s modified Eagle medium (DMEM) to a final
volume of 5 ml, and aerosolized using a compressor/
nebulizer system (Super Dandy Inhaler, PARI, Germany),
producing 67% of droplets with a diameter <5 μm,
according to the manufacturer.
Inhalation was facilitated by a face mask designed for
drug-inhalation in foals (Swevet Piab AB, Sweden). Follow-
ing challenge, calves were clinically monitored and samples
collected until PID 7, when they were euthanized.
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BRSV-Snk and monitored for seven days before euthan-
asia on PID 7, using the facilities and protocol described
for study 1 (except where otherwise noted). In addition
to these five calves (6 ± 3 weeks old), post-mortem (PM)
BAL samples were collected and analyzed from three
healthy calves (calves D1-3; 13 ± 4 weeks old), to act as
controls for BAL samples from BRSV infected animals
in study 2.
Euthanization was performed by an overdose of general
anesthesia (5 mg/kg ketamine and 15 mg/kg pentobarbital
sodium) followed by exsanguination.
Approval for both experiments were retained from the
Ethical Committee of the district court of Uppsala,
Sweden (Ref. no. C330/11). The ethical endpoint of both
experiments, defined as the condition when animals
would be euthanized prematurely, included: i) marked
abdominal dyspnea or respiratory rate >100/min, in
conjunction with severely depressed general state, or
ii) anorexia for >24 h, or iii) rectal temperature >41°C
for >36 h.
Clinical and pathological examination
Following challenge, daily clinical examinations were per-
formed on each calf, and numerical values were deter-
mined for a set of predetermined parameters reflecting
general state and respiratory disease (Table 1). Daily indi-
vidual clinical scores were calculated by summing these
numerical values multiplied by a coefficient for each par-
ameter (Table 1). Coefficient weights reflect parameter
association with disease severity in BRSV-infected calves
less than 3 months of age, based on observations during
natural BRSV-outbreaks [23]. Thus, general depression
and reduced or absent appetite in BRSV-infected calves
were considered moderate to severe signs of BRSV disease
with high clinical impact and poor prognosis (coefficients
of 4), abdominal dyspnea a moderate sign (coefficient of
3), and increased rectal temperature and respiratory rate,
mild to moderate signs (coefficients of 2). The other re-
corded parameters have varying clinical specificity and se-
verity, from mild to severe, but typically have little clinical
impact, and may be very transient. These parameters were
assigned a coefficient of 1 (Table 1). Individual accumu-
lated clinical scores (ACS) were calculated as the area
under daily clinical scores, using the Trapezoid method.
At PM examination, lung lesions were evaluated, recorded
and quantified, as previously described [24]. Tissue sam-
ples, preferentially from lesioned areas, were collected
from each of the lobes in the right lung and trachea, and
preserved in 5% paraformaldehyde.
Sampling
Serum was obtained from blood collected on PID −37, −15,
0 and 7, and stored at −20°C, until antibody analysis. Nasalsecretions were collected and stored at −70°C, as previously
described [21] using sterile cotton-tipped swabs daily from
PID 0 to 7, and tampons on PID 0 and 6.
In study 1 endoscopic BAL in sedated calves was per-
formed the day before challenge in all calves as previ-
ously described, including disinfection of the endoscope
between each calf [23], except lungs were flushed with
PBS with 120 μg/ml benzyl penicillin sodium. In both
study 1 and study 2 PM BAL was performed in all calves
as previously described [12], except lungs were flushed
using PBS. BAL fluid was stored on ice after recovery.
BAL cells in 10 ml BAL fluid were pelleted by centrifu-
gation (200 × g, 10 min), and resuspended in either
350 μl RLT buffer (Qiagen, Sweden) or 1 ml DMEM
with 20% fetal calf serum, and stored at −70°C. BAL
supernatant was recovered from centrifugation and stored
at −70°C. Bacterial culture was attempted by inoculating
bovine blood agar plates with 1 ml of unprocessed BAL
fluid.
Detection of BRSV-specific antibodies
BRSV-specific IgG1 antibodies were analyzed using a
commercial ELISA kit (SVANOVIR® BRSV-Ab ELISA,
Svanova, Sweden), in accordance with the manufacturer’s
instructions, including calculations of corrected optic
density (COD) and percent of kit positive control (%COD
positive).
Detection and isolation of virus
BRSV-F gene RNA present in nasal secretions or in BAL
cells corresponding to 10 ml of BAL, was quantified by
RT-qPCR as previously described [21], and expressed as
TCID50 equivalent units to dilutions of a virus sample
with known titer. Accumulated virus shed (AVS) was
calculated as the area under individual curves of BRSV
detected by RT-qPCR in nasal secretions from PID 0 to
PID 7. Virus isolation was attempted by inoculating bo-
vine turbinate cells with BAL and nasal secretion sam-
ples, as previously described [21]. Cultures of inoculated
bovine turbinate cells were examined daily, and were
considered positive if cytopathic effects appeared within
seven days.
Histological analysis
Lung and trachea tissue samples were fixed in 10% buffered
formalin, embedded in paraffin, sectioned and stained with
hematoxylin and eosin (HE) and by immunohistochemistry
(IHC) to detect BRSV antigen.
BRSV immunohistochemistry staining
For unmasking, sections were treated with heat-induced
epitope retrieval (HIER). They were placed in HIER buf-
fer (Target Retrieval Solution, pH = 6, DAKO, Sweden)
and subjected to heat treatment in HIER Microwave at
Table 1 Parameters and coefficients used to calculate clinical scores in BRSV infected calves
Clinical parameter Parameter coefficient State description Numerical value
General state 4 Normal 0
Moves slowly, head down 1
Lying down/staggers 2
Recumbent 3
Appetite 4 Normal 0
Reduced 1
Absent 2
Abdominal dyspnea 3 Normal 0
Slight (short, rapid) 1
Moderate (labored) 2
Severe (very labored, grunting) 3






















Nasal discharge 1 Normal 0
Slight uni-/bilat. serous 1
Moderate bilat. serous to purulent 2
Copious bilat. purulent 3
During clinical examination, each clinical parameter was assigned a numerical value according to the appropriate state description for that parameter. A clinical
score sum was then calculated, by multiplying each numerical value with the parameter coefficient.
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and were allowed to stand for 20 min at room temperature.
Endogenous peroxidase activity was blocked with 3%
hydrogen peroxide for 20 min at room temperature. Un-
specific antigen staining was blocked with 2% bovine
serum albumin (Sigma-Aldrich, Sweden AB) for 20 min.The slides were then incubated at room temperature for
45 min with mouse monoclonal antibody anti RSV (clone
5H5, 2G122, 5A6 and 1C3, NCL-RSV3, Novocastra, Leica
Microsystems, Sweden) diluted 1:100 in diluents buffer
(1% BSA/TBS pH= 7.6). The detection was conducted
with the dextran polymer method (EnVisionTM/mouse,
Figure 1 Daily and accumulated clinical score following aerosol
challenge with either BRSV-Snk or BRSV-Dk. Six calves were
experimentally infected with virulent BRSV, either passaged in vivo
(BRSV-Snk, n = 3, calves A1-3), or in vitro (BRSV-Dk, n = 3, calves B1-3).
Following infection on post-infection day (PID) 0, calves were monitored
for seven days. Daily clinical scores (panel A) were calculated from
observed clinical signs (see Tables 1 and 2). Accumulated clinical
scores, from PID 0 to PID 7 (panel B), were calculated as the area
under individual clinical score curves.
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benzidine substrate (DAB, DAKO, Sweden). Sections were
counterstained with haematoxylin. Antibody-omission
stained sections served as negative controls for each sec-
tion. Appropriate positive and negative control sections
were included in each run.
Scoring of histopathological severity of inflammation
The severity of histopathology was scored in each HE-
stained section, from 0 (normal), 1 (mild), 2 (moderate) to
3 (severe). The extent and localization of BRSV-antigen
was evaluated in IHC-stained sections. BAL cell type com-
position was determined by manual microscopic analysis
of stained cytospin preparations of BAL fluid.
Detection of cytokines in BAL supernatant
To enhance the sensitivity of cytokine detection, BAL
supernatant was concentrated 20X (BAL20X) by filtered
(UFC900324, Amicon Ultra-15, 3 kDa, Merck Millipore,
Sweden) centrifugation (swinging bucket rotor, 4000 × g,
25–30 min), to an equal final volume. Cytokines in
BAL20X were analyzed using commercially available ELISA
kits, and by following provided instructions for: interleukin
4 (IL-4; MCA5892KZZ Bovine Interleukin-4 ELISA,
BioRad, Sweden), interleukin 6 (IL-6; ESS0029 Bovine IL-
6 ELISA, Pierce, USA), interleukin 8 (IL-8; ABIN414016
Bovine IL-8 ELISA, Antibodies Online, Germany), tumor
necrosis factor alpha (TNFα; VS0285B-002 Bovine TNFα
ELISA, Divbio Science Europe, The Netherlands), and
interferon gamma (IFNγ; MCA5638KZZ Bovine IFNγ
ELISA, BioRad, Sweden). Cytokine concentration (ng/ml)
in each sample of BAL supernatant was calculated using
serial dilutions of supplied standards in each kit, and by
correcting for the concentration factor of the BAL20X.
Measuring lung function
Lung function was passively measured before and after
BRSV challenge, on PID 0 and 6, by the forced oscilla-
tion technique (EquineOsc Calf measurement head,
EEMS, Harts, UK), using the same face mask described
for aerosol inhalation. Values for resistance (R) and
reactance (X)(kPa/L/s) were obtained at 3, 5, 7 and
10 Hz, as described by Reinhold and colleagues [25].
Each calf was tested at least twice on each day and the
data sets with optimal coherence selected (coherence > 0.9;
majority of data sets > 0.97). In the event of clear artifacts
of breathing, such as cough or breath holding, the series
were repeated. Daily calibration was performed using a
2.26 m long tube, with a 21 mm internal diameter.
Ranking of infected calves
To encompass the three major aspects of BRSV-
infection clinical signs, lung pathology and virus replica-
tion, the six calves in study 1 (calves A1-3 and B1-3)were ranked from least affected (1) to most affected (6)
based on: accumulated clinical scores recorded from
PID 0 to PID 7; degree of consolidative lesions in lungs
on PID 7; and accumulated virus detected in nasal secre-
tions from PID 0 to PID 7. Group rank sums were then
calculated for each rank, and for all three ranks (total
rank sum).
Statistical analysis
Where not otherwise stated, results are presented as
group mean ± standard deviation (SD). For results pre-
sented as a percentage of a whole, SD is presented in
percentage points (pp). Statistically significant differences
were determined using either one-way ANOVA followed
by Student’s t-test, or pairwise t-test, or Kruskal–Wallis
analysis followed by Wilcoxon test (JMP 10 for Mac, SAS
Institute Inc.). Significance was assumed when p ≤ 0.05
and tendency when p ≤ 0.1.
Results
Study 1: Evaluation of clinical, pathological and
virological expression of two virulent BRSV inocula in
calves with low levels of MDA
Clinical signs following challenge
Following experimental infection, mild to severe clinical
signs of respiratory disease were observed in all infected
calves (Figure 1A). For all calves, upper respiratory signs,
such as nasal discharge and coughing, as well as ocular
discharge were observed on PID 3–5. In BRSV-Snk in-
fected calves, these progressed to severe respiratory signs
on PID7, whereas clinical signs were more moderate on
PID 7 in calves infected with BRSV-Dk (Table 2).
Table 2 Clinical scores in calves on day seven after
experimental infection with BRSV
Group/Calf
BRSV-Snk BRSV-Dk
Clinical sign A1 A2 A3 B1 B2 B3
General state 1 1 1 0 1 0
Appetite 1 1 1 0 0 0
Abdominal dyspnea 2 2 2 2 2 2
Temperature 0 4 0 0 1 2
Respiratory rate 3 3 3 1 3 0
Lung sounds intensity 2 3 3 0 2 1
Added lung sounds 0 3 2 0 2 1
Nasal discharge 1 2 1 1 1 1
Coughing 2 2 2 0 2 0
Clinical score 25 38 28 9 25 13
Six calves were experimentally infected with virulent BRSV, either passaged
in vivo (BRSV-Snk, n = 3, calves A1-3), or in vitro (BRSV-Dk, n = 3, calves B1-3).
Clinical signs were recorded daily for seven days, and scores calculated as
described in Table 1.
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BRSV-Snk infected calves had significantly higher (p ≤ 0.05)
accumulated clinical scores (Figure 1B).
Macroscopic and histological lung pathology
BRSV-Snk infected calves tended to have more extensive
consolidated lung lesions (38.5 ± 26.3% of total lung tis-
sue) on PID7, compared to calves infected with BRSV-
Dk (12.8 ± 14.6%), but this difference was not statistically
significant (p = 0.23; Figure 2A and C).
Histologically, lesions in the trachea in both groups of
calves consisted of degeneration and necrosis of epithe-
lium, and epithelial hyperplasia in some areas (Figure 2B:I
and II show representative pictures from BRSV-Snk and
BRSV-Dk infected animals, respectively). In the lungs,
BRSV-Snk infected calves showed extensive moderate to
severe bronchointerstitial pneumonia, as well as purulent
bronchitis and bronchiolitis (Figure 2B:III; representative
picture of lung, calf A2). BRSV-Dk infected calves showed
similar but less severe histopathological changes in the
lungs, ranging from mild to moderate (Figure 2B:IV;
representative picture of lung, calf B3).
In summary, BRSV-Snk infected animals tended to
have macroscopically more extensive, and histologically
more severe lung lesions, compared to BRSV-Dk in-
fected animals (Figure 2C), but with no discernible dif-
ference in the severity of histological inflammation in
the trachea.
Inflammatory cells in bronchoalveolar lavage
Bronchoalveolar lavage was performed to collect BAL
cells in all calves, once before infection (PID −1), andagain on the day of euthanization (PID 7). Regardless of
challenge inoculum, experimental infection altered the
composition of BAL cell types (Figure 2D). Before infec-
tion, the predominant BAL cell type were macrophages
(63.0 ± 26.0% for BRSV-Snk and 69.0 ± 10.1% for BRSV-
Dk), followed by neutrophils (30.0 ± 27.8% for BRSV-Snk
and 21.3 ± 18.5% for BRSV-Dk), whereas after infection,
neutrophils were the predominant BAL cell type (79.0 ±
4.4% for BRSV-Snk and 80.3 ± 6.0% for BRSV-Dk),
followed by macrophages (18.7 ± 2.3% for BRSV-Snk and
17.7 ± 4.5% for BRSV-Dk) (Figure 2D).
However, the total number of BAL cells was significantly
increased only in BRSV-Snk infected calves following chal-
lenge (6.9 ± 2.0 ×106 cells/ml at PID 7), compared to before
challenge (1.0 ± 0.2 ×106 cells/ml at PID −1; p ≤ 0.01; pair-
wise t-test), and compared to BRSV-Dk infected calves be-
fore and after challenge (1.1 ± 0.2 ×106 cells/ml at PID −1;
0.8 ± 0.7 ×106 cells/ml at PID 7; p ≤ 0.01; pairwise t-test;
Figure 2D).
Virology
RT-qPCR detection and isolation of BRSV in nasal secretion
and BAL
BRSV RNA was detected by RT-qPCR in nasal secre-
tions collected daily from PID 0 to PID 7, and in BAL
collected on PID 7 (PM BAL). In addition, BRSV was
isolated in the first passage in bovine turbinate cell cul-
ture, from all infected calves, in both nasal secretions
from PID 6, and PM BAL fluid. Attempted bacterial cul-
ture from BAL fluid indicated no bacterial coinfection in
the lungs of any of the calves. Two of the BRSV-Snk in-
fected calves (A2 and A3) started shedding virus on PID
2, and shed high amounts of virus (A2 log10 AVS 19.3
TCID50 equiv.; A3 log10 AVS 14.9 TCID50 equiv.), both
in nasal secretions and PM BAL, whereas the third
BRSV-Snk infected calf (A1), shed substantially less virus
(log10 AVS 3.6 TCID50 equiv.) (Figure 3A-B).
Compared to the two high-shedding BRSV-Snk in-
fected calves, calves infected with BRSV-Dk shed mark-
edly less virus in nasal secretions (B1, B2 and B3 log10
AVS 3.5, 9.4 and 11.1 TCID50 equiv., respectively), and
had less viral RNA in BAL, although this was not statis-
tically significant (Figure 3A-B).
BRSV immunostaining in lung and trachea sections
In IHC-stained sections of trachea very little or no
BRSV antigen was detected in BRSV-Snk infected calves
(Figure 3C:I is representative), whereas viral antigen was
abundant in sections of trachea from BRSV-Dk infected
calves (Figure 3C:II is representative). Conversely, whereas
viral antigen was abundant in the lungs of 2/3 BRSV-Snk
infected calves (Figure 3C:III is representative), very little
or no BRSV antigen was detected in the lungs from
BRSV-Dk infected calves (Figure 3C:IV is representative).
Figure 2 Pulmonary pathology and neutrophil influx in calves following aerosol challenge with either BRSV-Snk or BRSV-Dk. Calves
were experimentally infected as described in Figure 1. Calves were euthanized seven days after infection and the macroscopic extent of lung
lesions were documented (panel A). From each calf, trachea tissue and four lung tissue samples were collected for sectioning, staining and
histopathological description and scoring of severity of inflammation (1–3). Panels B:I-IV show representative HE-stained sections from: (B:I) trachea
from calf A2; (B:II) trachea from calf B3; (B:III) lung from calf A2; and (B:IV) lung from calf B3. Horizontal bars indicate 50 μm in panels B:I and B:II, and
100 μm in panels B:III and B:IV. Mean histopathological severity of inflammation per calf, is shown on the x-axis in panel C, along with the proportion
(%) of macroscopic lung lesions per calf on the y-axis. Bronchoalveolar lavage (BAL) was performed on PID −1 and PID 7, and cell types in BAL samples
enumerated (Panel D). Stacks represent the mean total number of cells in BAL per ml, with associated standard deviation, as well as the number of
neutrophils, macrophages and lymphocytes in BAL per ml. The proportion of eosinophils were <1% in all samples.
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Figure 3 Virus detected in the airways of calves after aerosol
challenge with either BRSV-Snk or BRSV-Dk. Calves were
experimentally infected as described in Figure 1. Daily nasal
secretion (NS) samples were collected for eight consecutive days,
starting on PID 0. After euthanization on PID 7, bronchoalveolar
lavage (BAL) was collected, along with tissue samples from the
trachea and lung, for histopathology and immunohistochemistry
(IHC) to demonstrate BRSV-antigen (brown stain). BRSV RNA in daily NS
(panel A) and BAL (x-axis, panel B) was detected by RT-qPCR, and is
expressed as log10 TCID50 equivalent unit. The accumulated virus shed
in NS (y-axis, panel B) was calculated as the area under individual
curves. Panels C:I-IV show representative IHC-stained sections of:
(C:I) trachea from calf A2; (C:II) trachea from calf B3; (C:III) lung
from calf A2; and (C:IV) lung from calf B2. Horizontal bars in panels
C:I-IV indicate 50 μm.
Figure 4 Serum anti-BRSV IgG1 in calves, before and after aerosol
challenge with either BRSV-Snk or BRSV-Dk. Calves were
experimentally infected as described in Figure 1. BRSV-specific IgG1
antibodies, detected by ELISA (SVANOVIR® BRSV-Ab ELISA, Boehringer
Ingelheim Svanova, Sweden) in serum diluted 1:25, are expressed as
percent of the corrected optical density (COD) of a positive control
sample. The shaded area of the chart indicates ≤10% COD of positive,
defined as negative by the kit manufacturer.
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BRSV antigen by IHC, both in the trachea and in the lungs
(data not shown).Serum BRSV-specific antibodies
All calves, except A1, had low and consistently decreas-
ing levels of BRSV-specific MDA, throughout the experi-
ment (Figure 4). In contrast, the BRSV-Snk infected calf
A1 (the oldest calf in study 1) seroconverted within
7 days after challenge, strongly suggesting that this calf
had been previously primed against BRSV.
Animal ranking
When calves were ranked from least affected (1) to most
affected (6) based on clinical score, degree of lung path-
ology and accumulated virus shed in nasal secretions,
two of the BRSV-Snk infected calves (A2 and A3) con-
sistently received the highest ranks (Figure 5A). Con-
versely, the calves infected with BRSV-Dk received low
ranks, as they demonstrated less severe clinical signs,
less lung pathology, and less virus shedding (Figure 5A).
The BRSV-Snk infected calf that rapidly seroconverted
following challenge (A1), received a high clinical rank,
an intermediate lung pathology rank, and a low viral-
shed rank (Figure 5A). Overall, the BRSV-Snk infected
calves ranked significantly higher, compared to calves in-
fected with BRSV-Dk (p ≤ 0.01; Figure 5B). Based on the
overall ability of the BRSV-Snk inoculum to induce
BRSV infection, it was chosen as the inoculum in study
2, to reproduce and characterize the model in calves
with moderate levels of MDA.
Study 2: Reproduction of clinical signs, virology and
pathology using aerosolized BRSV-Snk in calves with
passive immunity
Based on the high level of clinical signs of disease ob-
served in calves with low levels of MDA, following chal-
lenge with BRSV-Snk in study 1, an additional five calves
(calves C1-5), which were all BRSV-naive and had mod-
erate levels of BRSV-specific serum IgG1 MDA were
Figure 5 Clinical, pathological and virological ranking of calves
following aerosol challenge with either BRSV-Snk or BRSV-Dk.
Calves were experimentally infected as described in Figure 1. Following
challenge, calves were ranked (panel A) based on accumulated daily
clinical scores (Clinical rank), nasal virus shed (Viral-shed rank), and extent
of lung lesions (Pathology rank). Panel B shows the rank sum for each
of the three ranks, and the total rank sum per group.
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used in study 1.
Clinical signs, lung pathology and virology following
challenge
Clinical signs of disease and lung pathology, as well as
levels of viral RNA detected in the upper and lower air-
ways in study 2, following challenge of calves C1-5, have
been described in detail elsewhere [24]. The amplitude
and kinetics of these parameters were in line with observa-
tions in BRSV-Snk infected calves in study 1 (Figure 6A-C).
Briefly, all infected calves in study 2 developed clinical signs
of upper respiratory disease starting on PID 3–5, which
progressed to severe lower respiratory disease from PID 5
to PID 7 (Figure 6A). On PID 7, all five calves were moder-
ately to severely depressed (recumbent, and staggering
when prompted to rise), with reduced or absent appetite.
Although both groups of BRSV-Snk infected calves instudy 1 and 2 shed high amounts of virus, as detected by
RT-qPCR, calves in study 2 shed less accumulated virus in
nasal secretions compared to those in study 1 (log10 1.6
TCID50 eq. difference in mean), but more in BAL fluid on
PID 7 (log10 2.1 TCID50 eq. difference in mean). At post-
mortem, BRSV-Snk infected calves in study 2 had extensive
consolidated lung lesions and histopathological changes on
PID 7, similar in extent to those in study 1 (38.5 ± 26.3%
and 48.3 ± 12.0% of total lung area for study 1 and
study 2, respectively; Figure 6C; mean histological
score 2.7 ± 0.3 and 2.9 ± 0.1 for study 1 and study 2,
respectively; Figure 6C).
Quantitative assessment of lung function
The impact of lower respiratory disease (as demon-
strated by clinical signs of disease and lung pathology)
on lung function in the five calves in study 2 was evalu-
ated by the forced oscillation technique before and after
challenge (on PID 0 and 6). Following challenge, infected
animals demonstrated a tendency at 10 Hz measure-
ments for increased airway resistance (0.17 ± 0.03 kPa/L/
s on PID 0; 0.20 ± 0.06 kPa/L/s on PID 6; p = 0.2, pair-
wise t-test) and significantly decreased airway reactance
(0.03 ± 0.03 kPa/L/s on PID 0; −0.02 ± 0.04 kPa/L/s on
PID 6; p ≤ 0.05, pairwise t-test; Figure 7).
Cytology and cytokine profile in BAL
Seven days after experimental BRSV infection, BAL
was collected from all five infected calves in study 2,
and in addition, from three uninfected calves. BAL cell
types in cytospin preparations were analyzed by light
microscopy (Figure 8A) and BAL supernatant was ana-
lyzed using ELISAs, specific to bovine inflammatory
cytokines (Figure 8B-F).
Following infection, infected calves demonstrated a
significant increase in inflammatory cells in BAL
(11.0 ± 3.7 ×106 cells/ml), compared to uninfected con-
trols (1.1 ± 0.2 ×106 cells/ml) (p ≤ 0.005; Figure 8A). As
observed in BRSV-Snk infected calves in study 1, this
increase consisted mostly of neutrophils (68.6 ± 14.4%),
followed by macrophages (27.8 ± 13.0%) and lympho-
cytes (3.6 ± 2.0%). Very few eosinophils were seen in the
BAL of infected calves (<0.5%).
Cytokine analysis of BAL supernatant from infected
calves demonstrated significantly higher levels of IFNγ
(p ≤ 0.005; Figure 8E) and a tendency for higher levels of
IL-6 (p = 0.08; Figure 8C), compared to uninfected con-
trol calves. In contrast, levels of IL-4, IL-8 and TNFα in
BAL, did not differ from those of uninfected controls,
seven days after infection (Figure 8B,D and F).
Discussion
In the present paper, we describe an experimental model
of BRSV infection with strong clinical and pathological
Figure 6 BRSV-Snk challenge in calves with low or moderate passive immunity: clinical, virological and pathological outcomes. Experimental
challenge by inhalation of aerosolized BRSV passaged in gnotobiotic calves (BRSV-Snk) was performed in three calves (A1-3; study 1) with low levels of
BRSV-specific maternal antibodies (MDA), and later reproduced in five calves (C1-5; study 2) with moderate levels of MDA. Clinical scores (Panel A) and
BRSV RNA detected by RT-qPCR in nasal swab samples (Panel B), from the day of challenge (post-infection day or PID) 0 to PID 7. Individual values are
presented for calves C1-5, and mean values are presented for calves A1-3. For both groups of calves, panel C shows mean extent of macroscopic lung
lesions on the y-axis, expressed as a percent of total lung area, and the mean severity of histopathological inflammation, scored from 0 to 3, on
the x-axis. For mean values, vertical and horizontal lines indicate standard deviation.
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model combines and refines elements from previously
published studies, including aerosol inoculation, the use
of inoculum passaged in gnotobiotic calves, and methods
to monitor and quantify clinical, pathological and viro-
logical parameters [12,14,21]. We believe that this model
can serve to enable a better evaluation of vaccine andFigure 7 BRSV-Snk challenge in calves with low or moderate
passive immunity: effect on airway resistance and reactance.
Experimental challenge by inhalation of aerosolized BRSV passaged
in gnotobiotic calves (BRSV-Snk) was performed in five calves with
moderate levels of BRSV-specific maternal antibodies (MDA). Lung
function was measured using the forced oscillation technique, and a
tightly fitting face mask; before challenge on post-infection day (PID)
0, and after challenge, on PID 6. Resistance (Panel A) and reactance
(Panel B) at 10Hz were calculated and presented as kPa/L/s.antiviral safety and efficacy and further increase under-
standing of the pathogenesis of BRSV, and also of HRSV.
Regardless of the inoculum, all inoculated calves (n = 11),
in both studies, developed manifest BRSV disease. The
rapid seroconversion detected in calf A1 in study 1 indi-
cated that, in contrast to the other calves, this BRSV-Snk-
infected calf had been previously exposed to natural BRSV.
This highlights that, to ascertain BRSV naiveté by seromo-
nitoring in herds, seronegative sentinel animals need to be
regularly monitored during the entire lifespan of calves to
be included in experimental trials. This case also confirms
earlier reports [26,27] that a sufficient amount of MDA
can suppress detectable humoral immune responses, fol-
lowing BRSV infection in young calves, with the net effect
of declining MDA detected by ELISA. However, although
this previous priming appear to have provided some viro-
logical protection, compared to all other BRSV-Snk in-
fected calves, calf A1 demonstrated severe clinical disease
following BRSV infection, in the absence of any other de-
tected pathogen, contrary to previously published reports
[28,29]. In contrast, the moderate clinical signs, pathology
and virus shed observed in calf B1 following BRSV-Dk
challenge, may possibly be explained by favorable genetics,
with more efficient innate and cellular responses. Any pre-
vious BRSV exposure of calf B1, even if virus replication
was very limited, would have resulted in a rapid anamnes-
tic humoral immune response upon reinfection, as seen in
calf A1, and demonstrated elsewhere [24,30].
Figure 8 Variations of cells populations and cytokines in bronchoalveolar lavage (BAL) from calves challenged with BRSV-Snk.
Experimental challenge by inhalation of aerosolized BRSV passaged in gnotobiotic calves (BRSV-Snk) was performed in five calves with moderate
levels of BRSV-specific maternal antibodies (MDA). Samples of the cells populating the lower airways were collected via BAL seven days after infection,
and in addition, from three healthy uninfected calves (Control). Cells in BAL samples were analyzed by light microscopy (panel A), and expressed as
group mean ×106 cells/ml. The concentrations of indicated inflammatory cytokines in BAL sample supernatants were measured using specific ELISAs,
and are expressed in ng/ml: (panel B) interleukin (IL)-4; (panel C) IL-6; (panel D) IL-8; (panel E) interferon gamma (IFNγ); and (panel F) tumor necrosis
factor alpha (TNFα). Individual data are indicated by rings and group means by horizontal lines. Probability (p) of statistically significant differences
between groups is given in each panel, where p ≤ 0.05 was considered statistically significant.
Blodörn et al. BMC Veterinary Research  (2015) 11:76 Page 11 of 14Immunohistochemical staining for BRSV antigen in
study 1 showed a marked difference in localization of
virus on PID 7, where two BRSV-Snk infected calves had
large amounts of virus in the lungs and only small
amounts of virus in the trachea, while the reverse was
true for BRSV-Dk infected calves. This disparity in anti-
gen localization on PID 7 might be due to delayed pro-
gression of viral replication in BRSV-Dk infected calves.
This opens the possibility that BRSV-Dk infected calves
might have developed more severe clinical signs, if the
7-day challenge model had been abandoned and the
experiment had been prolonged. However, this would
contradict previous observations using the BRSV-Dk in-
oculum, which indicate a peak of clinical signs on PID 6
[20]. Nonetheless, virus was isolated and high quantities
of viral RNA were detected by RT-qPCR in samples
from the upper and lower airways from all infected
calves in both studies, including calves A1 and B1, al-
though BRSV-Snk infected calves from both studies shed
103 times more virus in nasal secretions than BRSV-Dk
infected calves.
Despite the differing data of calves A1 and B1, and al-
though the number of animals in the first study was low(n = 3 + 3), we concluded that BRSV-Snk infected calves
tended to be more severely affected in the 7-day experi-
mental infection model, compared to BRSV-Dk infected
calves, when summarizing clinical, pathological and viro-
logical parameters (Figure 5B). Thus, results from study
1 were reproduced in study 2, using aerosol inoculation
of the BRSV-Snk inoculum in an additional five BRSV-
naive calves, with moderate levels of MDA.
Using a minimal amount of aerosolized inoculum
(104.0 pfu for BRSV-Snk) to experimentally infect calves
with and without MDA, the kinetics of severe naturally
occurring BRSV infection in calves was recreated in this
study [4,31]. On PID 7, most calves were severely af-
fected, and all BRSV-Snk infected calves in study 2 were
demonstrating depression, anorexia, pyrexia, tachypnea,
abdominal dyspnea and wheezing lung sounds.
The high level of clinical expression in BRSV-Snk
infected calves was mirrored by the great extent of
macroscopic lung lesions and by the severity of histo-
pathological changes in the lungs on PID 7. Manifest
inflammation was further verified in BRSV-Snk infected
calves in study 2, with significantly increased numbers
of neutrophils, macrophages and lymphocytes in BAL,
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tion in calves [32].
At the peak of clinical signs, 7 days post infection, the
calves in study 2 also demonstrated an increase of IFNγ
and minimal amounts of IL-4 in BAL supernatant, which
agrees with previously reported responses to primary
BRSV infection in calves [33]. Previous studies have
shown that T lymphocytes migrating to the lung during
BRSV infection are predominantly IFNγ producing CD8
+ T cells [34,35], which have been shown to be important
for BRSV clearance [12,36]. However, at least a propor-
tion of the IFNγ detected in BAL supernatant in study 2,
may also have been produced by NK cells, or alveolar
macrophages, as have been shown in vitro with human
alveolar macrophages [37]. Similar to that seen in calves,
infants hospitalized with severe HRSV bronchiolitis, had
an increased frequency of IFNγ producing CD8+ T cells,
collected by nasal brush, compared to infants with milder
upper respiratory tract infections [38]. Thus, IFNγ in BAL
supernatant can serve as an objective measurement of
disease severity, following experimental BRSV challenge.
Elevated levels of TNFα, IL-6 and IL-8 in BAL or
serum have also been associated with clinical signs and
pathology caused by BRSV infection in calves [33,39,40].
The lack of detectable increases in these cytokines in
BAL supernatant on PID 7 in study 2 may have been
due to suboptimal timing of BAL collection, as another
study where 6 weeks old calves where infected with
BRSV reported TNFα and IL-6 concentrations in BAL
to peak on PID 9 and PID 3, respectively [41].
The patent pneumonia in the BRSV-Snk infected
calves following infection in study 2, as demonstrated by
clinical signs, lung pathology, and the inflammatory pic-
ture in BAL, also reduced the lung function of affected
animals; with increased airway resistance, and decreased
airway reactance, which is suggestive of bronchocon-
striction and obstructive airway processes [25,42]. The
objective measurement of lung function by the forced
oscillation technique can be a useful tool in further
quantifying the outcome of a BRSV challenge, and the
efficacy of vaccine candidates, in calves. Optimization of
materials (e.g. face mask and tubing) and methods (e.g.
frequencies used) could further improve the analysis,
and need to be investigated in a larger set of calves.
The relative potency of the BRSV-Snk inoculum might
be due to loss of virulence in the BRSV-Dk inoculum,
following passage in cell culture. This is supported by
previously published studies, which demonstrated a higher
level of clinical signs of respiratory disease in calves with
MDA, using the same mode of inoculation and the same
isolate as the BRSV-Dk inoculum, but with fewer passages
in vitro [21], and by propagation in fetal lung cells [20].
Loss of virulence following in vitro passage has been re-
ported in some studies for BRSV and HRSV [43,44], butnot in others [45,46], and likely depends on the type of
cells and number of passages, and may be associated with
alterations in protein expression and post-translational
modifications. The BRSV-Snk inoculum, in contrast to the
BRSV-Dk inoculum, had been passaged in gnotobiotic
calves.
Apart from the inoculum, challenge by aerosol inhal-
ation hinges on two principal factors: the quality of the
aerosol, and the quantity inhaled by each animal. Limited
experimental infection studies in calves, using similar
aerosolization of BRSV in conjunction with intratracheal
injection [47], indicate that virus is mainly deposited in
the upper airways using this method, with subsequent
progression of virus replication to the lower airways.
However, other studies using inhaled aerosols show that
droplets ≤5 μm in diameter (67% of droplets in the
present study) can reach the alveoli in humans [48], and
reach the whole lung when infecting steers with
aerosolized foot-and-mouth disease virus [49], and more
accurately reproduces the symptoms of natural infection,
compared to large droplet intranasal administration, when
human volunteers were infected with influenza [50]. Thus,
more research on the kinetics of natural BRSV infection is
needed, to complement experimental findings, and to
further elucidate the relevance of the model with regard
to BRSV pathogenesis.
To study the unmodified pathogenesis of BRSV, field-
like clinical signs are essential, and to calculate relevant
treatment effects in vaccine or antiviral trials, a mini-
mum clinical expression is required, making the model
presented herein highly relevant, in contrast to compar-
able models with less clinical signs [51-53], or compar-
able clinical expression, but less neutralizing MDA at
the time of challenge [7]. This cognate host calf model
might also provide further understanding about HRSV
in infants [54-56], with particular usefulness in the study
of RSV pathogenesis and pathological processes in the
lower airways, where data from infants is limited [57],
but also to evaluate candidate vaccines that utilize pro-
teins conserved across BRSV and HRSV [24].
Conclusions
In conclusion, we have established a BRSV model with a
severe clinical expression in calves with maternal anti-
bodies at the time of challenge. We furthermore de-
scribe tools to evaluate disease severity: consistently,
using a rigid and comprehensive clinical scoring system;
and objectively, using a passive lung function test and
IFNγ concentration in BAL, to complement established
parameters, such as extent of lung lesions and virus
shedding following challenge. These tools can be used
in future BRSV research and vaccine development stud-
ies and this model could also be valuable for the under-
standing of HRSV.
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